Nutritional Intervention Study with Argan Oil in Man: Effects on Lipids and ApolipoproteinsDerouiche A.a · Cherki M.a · Drissi A.a · Bamou Y.b · El Messal M.c · Idrissi-Oudghiri A.b · Lecerf J.M.d · Adlouni A.a
aLaboratoire de Recherche sur les Lipoprotéines, Faculté des Sciences Ben M’Sik, Casablanca, bHôpital Militaire Moulay Ismail, Meknès, et cLaboratoire de Biochimie, Faculté des Sciences Aïn Chock, Casablanca, Maroc; dService de Nutrition, Institut Pasteur de Lille, Lille, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Aim: To evaluate whether the consumption of virgin argan oil (VAO) is associated with a change in serum lipids and reduces the risk of cardiovascular disease in healthy Moroccans. Methods: Sixty volunteers consumed butter (25 g/day) during 2 weeks (stabilization period) and were randomly divided into two groups: the treatment group received 25 g/day of VAO during 3 weeks (intervention period), and the control group received 25 g/day of extra virgin olive oil (EVO). Throughout the study, weight, blood pressure, and daily food intake were measured. Serum total cholesterol and low- and high-density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I and B were measured at the end of each diet period. Results: Analysis of food intake showed that the daily diet is isocaloric for the butter regimen (2,537 ± 244 kcal/day) as well as for the VAO and EVO regimens (2,561± 246 and 2,560 ± 253 kcal/day, respectively). Analysis of the lipid intake showed a reduction in saturated fatty acids with VAO and EVO regimens (27 ± 1.4 and 26.4 ± 3.4%, respectively) as compared with the stabilization period (41.6 ± 2.4%). The analysis of serum lipids showed a significant increase in high-density lipoprotein cholesterol and apolipoprotein A-I in both VAO group (8.4%, p = 0.012, and 5.2%, p = 0.027, respectively) and EVO group (17.3%, p = 0.001, and 5.9%, p = 0.036, respectively). However, low-density lipoprotein cholesterol and apolipoprotein B (13.8%, p = 0.037, and 7.8%, p = 0.039, respectively) decreased significantly only in EVO group as compared with the stabilization period, while triglycerides decreased significantly by 17.5% (p = 0.039) only in VAO group. Conclusion: These results confirm the cholesterol-lowering effect of EVO and show for the first time the triglyceride-lowering effect of VAO in men.
© 2005 S. Karger AG, Basel
- Kushi LH, Lew RA, Stare FJ, et al: Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med 1985;312:811–818.
Keys A: L’épidémiologie cardiovasculaire des matières grasses dans le régime alimentaire et les décès dus aux affections coronaires. Méd Chir Dig 1982;11:597–599.
- Esrey KL, Joseph L, Grover SA: Relationship between dietary intake and coronary heart disease mortality. Lipid Research Clinics Prevalence Follow-Up Study. J Clin Epidemiol 1996;49:211–216.
- Trautwein EA, Rieckhoff D, Kunath-Rau A, Erbersdobler HF: Replacing saturated fat with PUFA-rich (sunflower oil) or MUFA-rich (rapeseed, olive and high-oleic sunflower oil) fats resulted in comparable hypocholesterolemic effects in cholesterol-fed hamsters. Ann Nutr Metab 1999;43:159–172.
- Keys A, Minotti A, Karvonen MJ: The diet and 15-year death rate in the Seven Countries Study. Am J Epidemiol 1996;124:903–915.
- Nagyova A, Haban P, Klvanova J, Kadrabova J: Effects of dietary extra virgin olive oil on serum lipid resistance to oxidation and fatty acid composition in elderly lipidemic patients. Bratisl Lek Listy 2003;104:218–221.
- Olivier MF: Dietary fat and coronary heart disease. Cardiology 1987;74:22–27.
- Demaison L, Moreau D: Dietary n-3 polyunsaturated fatty acids and coronary heart disease-related mortality: A possible mechanism of action. Cell Mol Life Sci 2002;59:463–477.
- Baudet M, Dachet C, Lasserre M, Jacotot B: Modification in the composition and metabolic properties of human low density and high density lipoproteins by different fats. J Lipid Res 1984;25:456–468.
- Esteva O, Baudet M, Lasserre M, Jacotot B: Influence of the fatty acid composition of high-density lipoprotein phospholipids on the cholesterol efflux from cultured fibroblasts. Biochim Biophys Acta 1986;875:174–182.
- Khallouki F, Younos C, Soulimani R, Oster T, Charrouf Z, Spiegelhalder B, Bartsch H, Owen RW: Consumption of argan oil (Morocco) with its unique profile of fatty acids, tocopherols, squalene, sterols and phenolic compounds should confer valuable cancer chemopreventive effects. Eur J Cancer Prev 2003;12:67–75.
Répertoire général des aliments – Ciqual – 1991. Paris, Lavoisier-INRA, 1991.
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
Berrada Y, Settaf A, Baddouri K, Cherrah Y, Hassar M: L’huile d’argan normalise les pressions artérielles systolique et diastolique des rats spontanément hypertendus. Pharmacologie 1999;47:75–78.
Benajiba N, Morel S, De Leiris J, Charrouf Z, Agnaou H: Effet de l’huile d’argan sur la fonction cardiaque au cours de l’ischémie et de la perfusion. Thérapie 2002;57:246–252.
- Lasserre M, Mendy F, Spielmann D, Jacotot B: Effects of different dietary intake of essential fatty acids on C20:3 omega 6 and C20:4 omega 6 serum levels in human adults. Lipids 1985;20:227–233.
Berrada Y, Settaf A, Baddouri K, Cherrah Y, Hassar M: Mise en évidence expérimentale des effets antihypertenseurs et hypocholestérolémiants de l’huile d’argan, Argania sideroxylon. Thérapie 2000;55:375–378.
- Ferrara LA, Raimondi AS, d’Episcopo L, Guida L, Dello Russo A, Marotta T: Olive oil and reduced need for antihypertensive medications. Arch Intern Med 2000;160:837–842.
- Ostlund RE Jr, Racette SB, Stenson WF: Effects of trace components of dietary fat on cholesterol metabolism: Phytosterols, oxysterols, and squalene. Nutr Rev 2002;60:349–359.
- Plat J, Mensink RP: Effects of plant sterols and stanols on lipid metabolism and cardiovascular risk. Nutr Metab Cardiovasc Dis2001;11:31–40.
- Drissi A, Girona J, Cherki M, Godàs G, Derouiche A, El Messal M, Saile R, Kettani A, Solà R, Masana L, Adlouni A: Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (Argania spinosa). Clin Nutr 2004;23:1159–1166.
Wardlaw GM, Snook JT: Effect of diets high in butter, corn oil, or high-oleic acid sunflower oil on serum lipids and apolipoproteins in men.Am J Clin Nutr 1990;51:815–821.
- Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–219.
Muller M: Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 1998;19(suppl H):H18–H22.
- Berrougui H, Ettaib A, Herrera Gonzalez MD, Alvarez de Sotomayor M, Bennani-Kabchi A, Hmamouchi M: Hypolipidemic and hypocholesterolemic effect of argan oil (Argania spinosa L.) in Meriones shawi rats. J Ethnopharmacol 2003;89:15–18.
- Miller N: The evidence for the antiatherogenicity of high-density lipoprotein in man. Lipids 1978;13:914–919.
- Brousseau ME, Stucchi AF, Vespa DB, Schaefer EJ, Nicolosi RJ: A diet enriched in monounsaturated fats decreases low-density lipoprotein concentrations in cynomolgus monkeys by a different mechanism than does a diet enriched in polyunsaturated fats. J Nutr 1993;123:2049–2058.
- Cowin IS, Emmett PM; ALSPAC Study Team; Avon Longitudinal Study of Pregnancy and Childhood: Associations between dietary intakes and blood cholesterol concentrations at 31 months. Eur J Clin Nutr 2001;55:39–49.
- Bunyard LB, Dennis KE, Nicklas BJ: Dietary intake and changes in lipoprotein lipids in obese, postmenopausal women placed on an American Heart Association Step 1 diet. J Am Diet Assoc 2002;102:52–57.
- Barkia A, Puchois P, Ghalim N, Torpier G, Barbaras R, Ailhaud G, Fruchart JC: Differential role of apolipoprotein A-I containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991;87:135–146.
Parra H, Fievet C, Boniface B, Bertrand M, Duthieul P, Fruchart JC: Lipoproteins, apolipoproteins and coronary artery disease assessed by coronary arteriography; in De Genes JL, et al (eds): Latent Dyslipoproteinemias and Atherosclerosis. New York, Raven Press, 1984, pp 187–189.
- Osada J, Fernandez-Sanchez A, Diaz-Morillo JL, Aylagas H, Miro-Obradors MJ, Ordovas J, Palacios-Alaiz E: Hepatic expression of apolipoprotein A-I gene in rats is upregulated by monounsaturated fatty acid diet. Biochem Biophys Res Commun 1991;180:162–168.
- Calleja L, Trallero MC, Carrizosa C, Mendez M, Palacios-Alaiz E, Osada J: Effects of dietary fat amount and saturation on the regulation of hepatic mRNA and plasma apolipoprotein A-I in rats. Atherosclerosis 2000;152:69–78.
- Puiggros C, Chacon P, Armadans LI, Clapes J, Planas M: Effects of oleic-rich and omega-3-rich diets on serum lipid pattern and lipid oxidation in mildly hypercholesterolemic patients. Clin Nutr 2002;21:79–87.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.